Aydin Nurten Nur, Aydin Murat
Department of Infectious Diseases and Clinical Microbiology, Erzurum Regional Training and Research Hospital, Erzurum, Turkiye.
North Clin Istanb. 2024 Oct 1;11(5):398-405. doi: 10.14744/nci.2023.82473. eCollection 2024.
Drug-drug interactions (DDIs) occur when one drug alters the effect of another drug. The aim of this study was to evaluate potential drug-drug interactions (pDDIs) associated with the use of systemic antibiotics in hospitalized patients.
The study included patients over the age of 18 who were hospitalized in our hospital on 12.07.2022 and were using at least two systemic drugs concurrently, with at least one being a systemic antibiotic. The study was conducted using the point prevalence method. The patients' medication was evaluated for pDDIs using the UpToDate/Lexicomp database system. According to this screening tool, pDDIs were classified into 4 groups according to their severity: B, C, D, and X, ranging from mild to severe.
Out of the 296 patients included in the study, at least one pDDI was detected in 190 patients (64.2%). One hundred seventy-seven patients (59.8%) had at least one pDDI with non-antibiotic drugs. Fifty-seven patients (19.3%) had at least one pDDI with antibiotics. One hundred and six patients (35.8%) had no drug interactions. Patients with pDDIs related to antibiotics had significantly higher age, number of comorbidities, total number of medications and number of antibiotics (p=0.010, p=0.004, p<0.001, p<0.001, respectively) compared to patients without pDDIs related to antibiotics (n=239). For antibiotics, potential pDDIs were observed 25, 75, 6, and 6 times in groups B, C, D, and X, respectively. Out of the total of 398 antibiotics, penicillins (24.9%, n=99) and cephalosporins (24.4%, n=97) were the most frequently used. Respectively, eight and two pDDIs were detected with these drugs. While quinolones were used 47 times (11.8%), 74 pDDIs (59.7%) were identified with quinolones. Out of the 47 patients who used quinolones, 37 had pDDIs with antibiotics. The most frequent pDDI with antibiotics was associated with the use of quinolone systemic corticosteroids (15 patients). The second most prevalent interaction involves quinolone-angiotensin converting enzyme inhibitors or angiotensin 2 receptor blockers (13 patients).
Antibiotics should be checked for pDDIs before being prescribed. While beta-lactam antibiotics are generally considered safer in terms of pDDIs, greater caution should be exercised, particularly when prescribing quinolones.
当一种药物改变另一种药物的作用时,就会发生药物相互作用(DDIs)。本研究的目的是评估住院患者使用全身用抗生素相关的潜在药物相互作用(pDDIs)。
该研究纳入了2022年7月12日在我院住院、年龄在18岁以上且同时使用至少两种全身用药物、其中至少一种为全身用抗生素的患者。该研究采用现患率方法进行。使用UpToDate/Lexicomp数据库系统对患者的用药进行pDDIs评估。根据该筛查工具,pDDIs根据其严重程度分为4组:B、C、D和X组,从轻度到重度。
在纳入研究的296例患者中,190例(64.2%)检测到至少一种pDDI。177例(59.8%)患者与非抗生素药物存在至少一种pDDI。57例(19.3%)患者与抗生素存在至少一种pDDI。106例(35.8%)患者没有药物相互作用。与无抗生素相关pDDIs的患者(n = 239)相比,有抗生素相关pDDIs的患者年龄、合并症数量、用药总数和抗生素数量显著更高(分别为p = 0.010、p = 0.004、p < 0.001、p < 0.001)。对于抗生素,B、C、D和X组分别观察到潜在pDDIs 25次、75次、6次和6次。在总共398种抗生素中,青霉素(24.9%,n = 99)和头孢菌素(24.4%,n = 97)是最常用的。分别检测到与这些药物相关的8例和2例pDDIs。喹诺酮类药物使用了47次(11.8%),但检测到与喹诺酮类药物相关的pDDIs有74例(59.7%)。在使用喹诺酮类药物的47例患者中,37例与抗生素存在pDDIs。与抗生素最常见的pDDI与喹诺酮类全身用糖皮质激素的使用有关(15例患者)。第二常见的相互作用涉及喹诺酮类-血管紧张素转换酶抑制剂或血管紧张素2受体阻滞剂(13例患者)。
在开具抗生素处方前应检查是否存在pDDIs。虽然β-内酰胺类抗生素在pDDIs方面通常被认为更安全,但应格外谨慎,尤其是在开具喹诺酮类药物时。